BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
BioCryst Pharmaceuticals, Inc. (BCRX)
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
biocryst.gcs-web.com/investor-relations
Company Research
Source: GlobeNewswire
RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) taking place in Orlando, Fla., from November 6-10, 2025. The data will include results from a second interim analysis of the APeX-P trial evaluating long-term prophylaxis with an oral granule formulation of once-daily ORLADEYO® (berotralstat) in pediatric patients with hereditary angioedema (HAE) aged 2 to BioCryst poster presentations include: Hereditary Angioedema Attack Rates in Children 2-12 with Oral Prophylactic Berotralstat Over One Year; ePoster #R089; Friday, November 7, 2:50–3:05 p.m. ET; Monitor #15, West Exhibit HallPsychosocial Impact of Hereditary Angioedema on Young Patients and Their Caregivers; ePoster #R102; Friday, November 7, 2:50–3:05 p.m. ET; Monitor #16, West Exhibit HallBurden of Attack for Yo
Show less
Read more
Impact Snapshot
Event Time:
BCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCRX alerts
High impacting BioCryst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
BCRX
News
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- BioCryst Pharmaceuticals (NASDAQ:BCRX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- BioCryst Pharmaceuticals (BCRX): Valuation Check After Positive APeX-P Pediatric ORLADEYO Trial Update [Yahoo! Finance]Yahoo! Finance
- BioCryst Receives Early Termination of HSR Waiting Period for Astria AcquisitionGlobeNewswire
- BioCryst Data Highlights Severe Psychosocial Burden of HAE on Pediatric Patients, Caregivers [Yahoo! Finance]Yahoo! Finance
BCRX
Earnings
- 11/3/25 - Beat
BCRX
Sec Filings
- 12/3/25 - Form 4
- 12/3/25 - Form 144
- 12/3/25 - Form 8-K
- BCRX's page on the SEC website